PMID- 19513509
OWN - NLM
STAT- MEDLINE
DCOM- 20090814
LR  - 20191210
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 22
IP  - 1
DP  - 2009 Jul
TI  - Overexpression of mitogen-activated protein kinase kinase 4 and nuclear 
      factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for 
      poor prognosis.
PG  - 89-95
AB  - This study aimed to investigate the expression and clinical significance of 
      mitogen-activated protein kinase kinase 4 MKK4 and nuclear factor-kappaB 
      (NF-kappaB) in patients with laryngeal squamous cell carcinoma (LSCC). We used 
      immunohistochemistry (IHC) to examine the expression of MKK4 and NF-kappaB in 78 
      LSCCs and their adjacent normal tissues. To clarify the validity of MKK4 and 
      NF-kappaB as determined by the IHC analysis, RT-PCR was performed on 21 tissues 
      randomly selected from the 78 LSCCs. The positive expression rates of MKK4 and 
      NF-kappaB in patients with LSCC were 67.9% (53/78) and 60.3% (47/78) 
      respectively, which were significantly higher than those in the adjacent normal 
      tissue (both P<0.01). The positive expression of MKK4 and NF-kappaB tended to be 
      associated positively with lymph node metastasis (both P<0.01) as well as T stage 
      (both P<0.01). The Spearman analysis indicated that the expression level of MKK4 
      was positively correlated with that of NF-kappaB significantly (rs=0.368, 
      P<0.01). Overall survival curves estimated by Kaplan-Meier showed that tumor 
      patients with low MKK4 and NF-kappaB expression in their tumor cells survive 
      significantly longer than patients with high MKK4 and NF-kappaB levels (P=0.027, 
      and P<0.01, respectively). In addition, multivariate Cox regression analysis 
      showed that N stage, T stage and NF-kappaB expression are significant independent 
      prognostic factors for overall survival (P<0.01, P=0.014, and P=0.027, 
      respectively). These findings suggested that the expression of MKK4 and NF-kappaB 
      may be considered as a useful prognostic marker of LSCC after surgical resection.
FAU - Huang, Chuang
AU  - Huang C
AD  - Department of Otolaryngology, The First Affiliated Hospital, Chongqing Medical 
      University, Chongqing, P.R. China.
FAU - Huang, Kun
AU  - Huang K
FAU - Wang, Chi
AU  - Wang C
FAU - Jiang, Zhen-Dong
AU  - Jiang ZD
FAU - Li, Xing-Xing
AU  - Li XX
FAU - Wang, Hong-Peng
AU  - Wang HP
FAU - Chen, Hong-Yan
AU  - Chen HY
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (NF-kappa B)
RN  - EC 2.7.12.2 (MAP Kinase Kinase 4)
RN  - EC 2.7.12.2 (MAP2K4 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Squamous Cell/*enzymology/genetics/mortality/secondary/therapy
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*enzymology/genetics/mortality/pathology/therapy
MH  - Lymphatic Metastasis
MH  - MAP Kinase Kinase 4/*analysis/genetics
MH  - Male
MH  - Middle Aged
MH  - NF-kappa B/*analysis/genetics
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Reproducibility of Results
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Up-Regulation
EDAT- 2009/06/11 09:00
MHDA- 2009/08/15 09:00
CRDT- 2009/06/11 09:00
PHST- 2009/06/11 09:00 [entrez]
PHST- 2009/06/11 09:00 [pubmed]
PHST- 2009/08/15 09:00 [medline]
PST - ppublish
SO  - Oncol Rep. 2009 Jul;22(1):89-95.